<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00813891</url>
  </required_header>
  <id_info>
    <org_study_id>MUHC - 1234 - RVH</org_study_id>
    <nct_id>NCT00813891</nct_id>
  </id_info>
  <brief_title>Efficacy of Ranibizumab in Combination With Photodynamic Therapy for Wet Age-Related Macular Degeneration</brief_title>
  <official_title>Efficacy of Ranibizumab (Lucentis) in Combination With Photodynamic Therapy for Neovascular Age-Related Macular Degeneration</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>McGill University Health Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>McGill University Health Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the investigators study is to look at the visual outcomes of Ranibizumab
      injections in combination with photodynamic therapy for the treatment of neovascular
      age-related macular degeneration.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The main cause of severe vision loss in patients with age-related macular degeneration (AMD)
      is the development of choroidal neovascularization (CNV). This debilitating form of AMD
      affects the macula lutea, the central part of the retina, which is responsible for high
      resolution visual acuity. Characteristic findings in neovascular AMD include the development
      of new, abnormal blood vessels in the choroid layer beneath the macula otherwise known as
      CNV.

      Current treatment options for this condition have included include laser therapy,
      photodynamic therapy (PDT), and intraocular injections (different types of anti-vascular
      endothelial growth factors) alone or in combination. While current treatments were
      demonstrated to slow the progression of vision loss, neither therapy was shown to
      significantly improve visual acuity.

      Given their different modes of action, it is believed that combination therapy of Ranibizumab
      with PDT may lead to better visual outcomes and may result in an improved effect in treating
      AMD and therefore may help decrease the need for monthly Ranibizumab injections. After the
      first injection, regardless of which group the patient has been assigned to, they will
      receive Ranibizumab injections at 4 week intervals if clinically indicated. The purpose of
      the this study is to evaluate the visual outcomes of intraocular Ranibizumab injections in
      combination with photodynamic therapy with verteporfin for the treatment of neovascular AMD.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>January 2009</start_date>
  <completion_date type="Anticipated">December 2009</completion_date>
  <primary_completion_date type="Anticipated">December 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean change from baseline at 6 months in the best corrected visual acuity (VA) score using an early treatment diabetic retinopathy study eye chart at a starting distance of 4 meters.</measure>
    <time_frame>Monthly for a total of 12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To determine the following: 1:Proportion of subjects who loose fewer than 15 letters from baseline visual acuity at 6 months 2: Proportion of subjects with VA of 20/200 or worse 3: Proportion of subjects with VA of 20/40 or better</measure>
    <time_frame>One year</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">180</enrollment>
  <condition>Macular Degeneration</condition>
  <condition>Visual Acuity</condition>
  <arm_group>
    <arm_group_label>Pre-PDT</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants in this group will receive an intraocular Ranibizumab injection one week prior to the first PDT with verteporfin.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Post-PDT</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants in this group will receive an intraocular Ranibizumab injection one week post the first PDT with verteporfin.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No PDT</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants in this group will receive an intraocular Ranibizumab injection with no accompanying PDT with verteporfin.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ranibizumab</intervention_name>
    <description>Intraocular injection of 0.5mg of Ranibizumab one week prior to PDT with verteporfin</description>
    <arm_group_label>Pre-PDT</arm_group_label>
    <other_name>Lucentis the brand name of Ranibizumab</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ranibizumab</intervention_name>
    <description>Intraocular injection of 0.5mg of Ranibizumab one week after PDT with verteporfin</description>
    <arm_group_label>Post-PDT</arm_group_label>
    <other_name>Lucentis the brand name of Ranibizumab</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ranibizumab</intervention_name>
    <description>Intraocular injection of 0.5mg of Ranibizumab with no accompanying PDT with verteporfin</description>
    <arm_group_label>No PDT</arm_group_label>
    <other_name>Lucentis the brand name of Ranibizumab</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  diagnosed with any subtype of primary subfoveal or juxtafoveal choroidal
             neovascularization

          -  must be 50 years of age or older

          -  have a lesion whose total size is no more than 5400micrometres in greatest linear
             dimension in the study eye

          -  CNV that is more than 50% obscured by blood

          -  have best corrected visual acuity of 20/50-20/320 (Snellen equivalent)

          -  have been assessed with the use of early treatment diabetic retinopathy study charts

        Exclusion Criteria:

          -  previous treatment (including verteporfin therapy) that could compromise an assessment
             of the study treatment

          -  any permanent structural damage to the central fovea
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John Galic, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Montreal Retina Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>John Chen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Montreal Retina Institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>John Galic, MD</last_name>
    <phone>514-285-8866</phone>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Karin Oliver, MD</last_name>
    <phone>514-285-8866</phone>
    <email>karin.oliver@hotmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The Royal Victoria Hospital and the Montreal Retinal Institute</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3Z 1P4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <link>
    <url>http://www.muhc.ca/pfv/rvh/</url>
    <description>Royal Victoria Hospital is one of the sites that the study will take place.</description>
  </link>
  <reference>
    <citation>Bressler NM, Bressler SB, Congdon NG, Ferris FL 3rd, Friedman DS, Klein R, Lindblad AS, Milton RC, Seddon JM; Age-Related Eye Disease Study Research Group. Potential public health impact of Age-Related Eye Disease Study results: AREDS report no. 11. Arch Ophthalmol. 2003 Nov;121(11):1621-4.</citation>
    <PMID>14609922</PMID>
  </reference>
  <reference>
    <citation>Klein R, Peto T, Bird A, Vannewkirk MR. The epidemiology of age-related macular degeneration. Am J Ophthalmol. 2004 Mar;137(3):486-95. Review.</citation>
    <PMID>15013873</PMID>
  </reference>
  <reference>
    <citation>Congdon N, O'Colmain B, Klaver CC, Klein R, Muñoz B, Friedman DS, Kempen J, Taylor HR, Mitchell P; Eye Diseases Prevalence Research Group. Causes and prevalence of visual impairment among adults in the United States. Arch Ophthalmol. 2004 Apr;122(4):477-85.</citation>
    <PMID>15078664</PMID>
  </reference>
  <reference>
    <citation>Friedman DS, O'Colmain BJ, Muñoz B, Tomany SC, McCarty C, de Jong PT, Nemesure B, Mitchell P, Kempen J; Eye Diseases Prevalence Research Group. Prevalence of age-related macular degeneration in the United States. Arch Ophthalmol. 2004 Apr;122(4):564-72. Erratum in: Arch Ophthalmol. 2011 Sep;129(9):1188.</citation>
    <PMID>15078675</PMID>
  </reference>
  <reference>
    <citation>Bressler NM. Age-related macular degeneration is the leading cause of blindness... JAMA. 2004 Apr 21;291(15):1900-1.</citation>
    <PMID>15108691</PMID>
  </reference>
  <reference>
    <citation>Resnikoff S, Pascolini D, Etya'ale D, Kocur I, Pararajasegaram R, Pokharel GP, Mariotti SP. Global data on visual impairment in the year 2002. Bull World Health Organ. 2004 Nov;82(11):844-51. Epub 2004 Dec 14.</citation>
    <PMID>15640920</PMID>
  </reference>
  <reference>
    <citation>Yannuzzi LA, Negrão S, Iida T, Carvalho C, Rodriguez-Coleman H, Slakter J, Freund KB, Sorenson J, Orlock D, Borodoker N. Retinal angiomatous proliferation in age-related macular degeneration. Retina. 2001;21(5):416-34.</citation>
    <PMID>11642370</PMID>
  </reference>
  <reference>
    <citation>Holz FG, Pauleikhoff D, Klein R, Bird AC. Pathogenesis of lesions in late age-related macular disease. Am J Ophthalmol. 2004 Mar;137(3):504-10. Review.</citation>
    <PMID>15013875</PMID>
  </reference>
  <reference>
    <citation>Lopez PF, Sippy BD, Lambert HM, Thach AB, Hinton DR. Transdifferentiated retinal pigment epithelial cells are immunoreactive for vascular endothelial growth factor in surgically excised age-related macular degeneration-related choroidal neovascular membranes. Invest Ophthalmol Vis Sci. 1996 Apr;37(5):855-68.</citation>
    <PMID>8603870</PMID>
  </reference>
  <reference>
    <citation>Frank RN, Amin RH, Eliott D, Puklin JE, Abrams GW. Basic fibroblast growth factor and vascular endothelial growth factor are present in epiretinal and choroidal neovascular membranes. Am J Ophthalmol. 1996 Sep;122(3):393-403.</citation>
    <PMID>8794712</PMID>
  </reference>
  <reference>
    <citation>Kvanta A, Algvere PV, Berglin L, Seregard S. Subfoveal fibrovascular membranes in age-related macular degeneration express vascular endothelial growth factor. Invest Ophthalmol Vis Sci. 1996 Aug;37(9):1929-34.</citation>
    <PMID>8759365</PMID>
  </reference>
  <reference>
    <citation>Kliffen M, Sharma HS, Mooy CM, Kerkvliet S, de Jong PT. Increased expression of angiogenic growth factors in age-related maculopathy. Br J Ophthalmol. 1997 Feb;81(2):154-62.</citation>
    <PMID>9059252</PMID>
  </reference>
  <reference>
    <citation>Otani A, Takagi H, Oh H, Koyama S, Ogura Y, Matumura M, Honda Y. Vascular endothelial growth factor family and receptor expression in human choroidal neovascular membranes. Microvasc Res. 2002 Jul;64(1):162-9.</citation>
    <PMID>12074642</PMID>
  </reference>
  <reference>
    <citation>Rakic JM, Lambert V, Devy L, Luttun A, Carmeliet P, Claes C, Nguyen L, Foidart JM, Noël A, Munaut C. Placental growth factor, a member of the VEGF family, contributes to the development of choroidal neovascularization. Invest Ophthalmol Vis Sci. 2003 Jul;44(7):3186-93.</citation>
    <PMID>12824270</PMID>
  </reference>
  <reference>
    <citation>Okamoto N, Tobe T, Hackett SF, Ozaki H, Vinores MA, LaRochelle W, Zack DJ, Campochiaro PA. Transgenic mice with increased expression of vascular endothelial growth factor in the retina: a new model of intraretinal and subretinal neovascularization. Am J Pathol. 1997 Jul;151(1):281-91.</citation>
    <PMID>9212753</PMID>
  </reference>
  <reference>
    <citation>Schwesinger C, Yee C, Rohan RM, Joussen AM, Fernandez A, Meyer TN, Poulaki V, Ma JJ, Redmond TM, Liu S, Adamis AP, D'Amato RJ. Intrachoroidal neovascularization in transgenic mice overexpressing vascular endothelial growth factor in the retinal pigment epithelium. Am J Pathol. 2001 Mar;158(3):1161-72.</citation>
    <PMID>11238064</PMID>
  </reference>
  <reference>
    <citation>Krzystolik MG, Afshari MA, Adamis AP, Gaudreault J, Gragoudas ES, Michaud NA, Li W, Connolly E, O'Neill CA, Miller JW. Prevention of experimental choroidal neovascularization with intravitreal anti-vascular endothelial growth factor antibody fragment. Arch Ophthalmol. 2002 Mar;120(3):338-46.</citation>
    <PMID>11879138</PMID>
  </reference>
  <reference>
    <citation>Saishin Y, Saishin Y, Takahashi K, Lima e Silva R, Hylton D, Rudge JS, Wiegand SJ, Campochiaro PA. VEGF-TRAP(R1R2) suppresses choroidal neovascularization and VEGF-induced breakdown of the blood-retinal barrier. J Cell Physiol. 2003 May;195(2):241-8.</citation>
    <PMID>12652651</PMID>
  </reference>
  <reference>
    <citation>Verteporfin Roundtable 2000 and 2001 Participants; Treatment of age-related macular degeneration with photodynamic therapy (TAP) study group principal investigators; Verteporfin in photodynamic therapy (VIP) study group principal investigators. Guidelines for using verteporfin (visudyne) in photodynamic therapy to treat choroidal neovascularization due to age-related macular degeneration and other causes. Retina. 2002 Feb;22(1):6-18. Review.</citation>
    <PMID>11884872</PMID>
  </reference>
  <results_reference>
    <citation>Gragoudas ES, Adamis AP, Cunningham ET Jr, Feinsod M, Guyer DR; VEGF Inhibition Study in Ocular Neovascularization Clinical Trial Group. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med. 2004 Dec 30;351(27):2805-16.</citation>
    <PMID>15625332</PMID>
  </results_reference>
  <results_reference>
    <citation>Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, Kim RY; MARINA Study Group. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006 Oct 5;355(14):1419-31.</citation>
    <PMID>17021318</PMID>
  </results_reference>
  <results_reference>
    <citation>Brown DM, Kaiser PK, Michels M, Soubrane G, Heier JS, Kim RY, Sy JP, Schneider S; ANCHOR Study Group. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med. 2006 Oct 5;355(14):1432-44.</citation>
    <PMID>17021319</PMID>
  </results_reference>
  <verification_date>December 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 22, 2008</study_first_submitted>
  <study_first_submitted_qc>December 22, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 23, 2008</study_first_posted>
  <last_update_submitted>December 22, 2008</last_update_submitted>
  <last_update_submitted_qc>December 22, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 23, 2008</last_update_posted>
  <responsible_party>
    <name_title>McGill University Health Center</name_title>
    <organization>McGill Ophthalmology</organization>
  </responsible_party>
  <keyword>ranibizumab</keyword>
  <keyword>verteporfin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Degeneration</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ranibizumab</mesh_term>
    <mesh_term>Verteporfin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

